<unk> <unk>  (EPA), the active metabolite of<unk>  (E-EPA), like other omega-3 fatty<unk>  based drugs, appears to reduce production of triglycerides in the liver and to enhance clearance of triglycerides from circulating very low-density lipoprotein (VLDL) particles. The way it does that is not clear, but potential mechanisms include increased breakdown of fatty<unk> s; inhibition of diglyceride acyltransferase, which is involved in biosynthesis of triglycerides in the liver; and increased activity of lipoprotein lipase in blood.
Ethyl eicosapentaenoic acid
Ellagic acid
Fish oil 
Fish oil
Soybean oil
Etiocholanolone
Conjugated linoleic acid
Retinyl palmitate